ANAVEX-371 is under clinical development by Anavex Life Sciences and currently in Phase I for Frontotemporal Dementia (FTD). According to GlobalData, Phase I drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ANAVEX-371 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANAVEX-371 overview
ANAVEX 3-71 (AF-710B) is under development for the treatment of Alzheimer's disease, pick disease (frontotemporal dementia), Schizophrenia and Parkinson's disease. The drug candidate targets sigma-1 receptor and M1 muscarinic. The drug candidate is developed based on SIGMACEPTOR discovery platform technology. It is administered through oral route.
Anavex Life Sciences overview
Anavex Life Sciences (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous systems (CNS) diseases, pain, and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X syndrome, Angelman syndrome, visceral pain, multiple sclerosis, depression, stroke, frontotemporal dementia, acute and neuropathic Pain and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.
For a complete picture of ANAVEX-371’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
